Immunotherapy may yield longer treatment-free survival than targeted therapy in advanced renal cell carcinoma patients
Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients ...
Nov 10, 2021
0
2